Form 4: Alaunos VP of Finance Boosts Stake with Share & Option Grants

Alaunos Therapeutics' Vice President of Finance, Ferdinand Groenewald, acquired 10,775 shares of common stock and 4,000 employee stock options.

Summary

• Ferdinand Groenewald, Vice President of Finance at Alaunos Therapeutics, Inc. (TCRT), acquired 10,775 shares of common stock.
• The common stock acquisition occurred on August 18, 2025, at a price of $0.00 per share.
• Groenewald also acquired 4,000 employee stock options on August 18, 2025, with an exercise price of $2.32 per share.
• The options begin vesting on November 18, 2025, with one-sixteenth of the shares vesting in equal quarterly installments from August 18, 2025.
• Vesting is contingent upon Groenewald's continued service through each vesting date.
• The employee stock options have an expiration date of August 17, 2035.

Sentiment

Score: 7

Explanation: The acquisition of common stock and employee stock options by a key executive indicates confidence in the company's future performance and aligns management's interests with shareholders.

Positives

• The acquisition of 10,775 common shares at $0.00 indicates a direct grant or award, increasing the insider's direct ownership.
• The grant of 4,000 employee stock options provides a long-term incentive for the Vice President of Finance, aligning their interests with shareholder value creation.
• Insider acquisition of shares and options generally signals confidence in the company's future prospects from a key management member.

Future Outlook

The employee stock options will vest in equal quarterly installments over a period starting from August 18, 2025, with the first vesting on November 18, 2025, subject to the reporting person's continued service.

Related Party Transactions

• Ferdinand Groenewald, Vice President of Finance, acquired common stock and employee stock options from Alaunos Therapeutics, Inc., representing a compensation-related transaction between an insider and the company.

Stakeholder Impact

• Shareholders: Potentially positive, as insider acquisition can signal management confidence and alignment of interests.
• Employees: Positive for the reporting person due to equity compensation, which can serve as a retention and performance incentive.

Next Steps

• Continued service of the Vice President of Finance for vesting of stock options.
• Quarterly vesting of employee stock options beginning November 18, 2025.

Key Dates

Recommendation

The acquisition of common stock and employee stock options by a key executive, the Vice President of Finance, signals strong insider confidence in Alaunos Therapeutics' future prospects. This direct increase in personal stake aligns management's interests with shareholders and suggests a belief in the company's long-term value, making it a positive indicator for potential investors.

Keywords

Alaunos Therapeutics, TCRT, insider transaction, stock options, common stock, equity compensation, SEC Form 4, beneficial ownership